Cheapest GLP-1

Summary: For US adults paying cash in 2026, the cheapest legal GLP-1 is a LillyDirect Zepbound vial at $299 to $449 a month, with NovoCare Wegovy at $199 starter and $349 ongoing as the semaglutide alternative.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: in 2026, the cheapest legal GLP-1 for most US adults paying cash is a LillyDirect Self Pay Zepbound vial at $299 a month for the 2.5 mg starter, $399 for 5 mg, and $449 for the 7.5 to 15 mg vials ^[1]. The runner-up for people who want semaglutide instead of tirzepatide is NovoCare Pharmacy Wegovy at $199 for the first two months and $349 every month after that ^[2]. If you have commercial insurance and a qualifying diagnosis, a manufacturer savings card beats both of those, dropping the copay as low as $25 a month ^[5].

Everything else marketed as cheaper, including the $99 compounded telehealth offers, comes with tradeoffs that change the real number. Below is the situation-by-situation breakdown.

The 2026 cheapest-GLP-1 ranking, at a glance

The two lines that matter most for the median American without insurance are line one and line two. The two manufacturer cash programs are the only routes that combine FDA-approved drug, legal supply chain, and a price that is not $1,000.

LillyDirect Self Pay Zepbound vials: the cheapest legal tirzepatide

Eli Lilly launched single-dose Zepbound vials through LillyDirect in 2024 and the program is still the floor for FDA-approved tirzepatide in 2026 ^[1]. You skip the auto-injector pen, draw the dose yourself from a vial with a U-100 insulin syringe, and pay roughly half of what a pen costs at retail.

The drug in the vial is identical to the drug in a Zepbound auto-injector. The pen exists for convenience, not pharmacology. You pay for the device. Skip the device, save 50 to 60 percent.

Who this is for. Adults with a BMI of 30 or higher (or 27 plus a comorbidity) who want FDA-approved tirzepatide and are willing to handle a syringe. You order through LillyDirect.com after a brief telehealth consult or by uploading a prescription from your own doctor. Lilly ships the vials directly to your home in temperature-controlled packaging.

Who it is not for. People who cannot self-inject from a vial, people who need pharmacist counseling at a brick-and-mortar pharmacy, and anyone whose insurance already covers Zepbound at a copay under about $300. If your plan covers Zepbound at $50, do not pay $299 cash.

NovoCare Self Pay Wegovy: the cheapest brand semaglutide

Novo Nordisk runs an analogous cash-pay program for Wegovy under the NovoCare Pharmacy banner ^[2]. The pricing structure is different from LillyDirect. There is an introductory price for the first two fills, then the steady-state price applies.

NovoCare ships pre-filled Wegovy pens, not vials. That is the operational difference from LillyDirect. If you prefer a click-and-press pen to drawing from a vial, NovoCare is the path. The medication is the same semaglutide that goes into a $1,300 retail pen, just sold direct to the patient at a cash price that bypasses the pharmacy benefit manager markup.

Wegovy is FDA-approved for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, and for adolescents 12 and older with obesity. The NovoCare program follows the same indication, so a qualifying diagnosis is required.

Manufacturer savings cards: $25 a month if you fit the profile

If you have commercial insurance (employer-sponsored or a marketplace plan, not Medicare and not Medicaid) and a diagnosis the manufacturer covers, the savings card is the lowest legal price on the market ^[5].

The catch is the underlying insurance coverage. The savings card is a coupon that stacks on top of an active prescription benefit. If your plan excludes GLP-1s for weight-loss indications, the card alone will not bridge the full retail price. Mounjaro and Ozempic for type 2 diabetes are covered by most commercial plans, which is why those two cards routinely deliver the $25 outcome. Zepbound and Wegovy for obesity are covered by fewer plans, so the card is hit-or-miss until you confirm coverage.

How to actually verify before you commit:

1. Call the pharmacy benefits number on your insurance card. Ask whether your specific GLP-1 is covered for your specific indication, and what the copay tier is.
2. If covered, apply for the savings card on the manufacturer site (Mounjaro.com, Zepbound.com, NovoCare.com).
3. Bring the card to the pharmacy at fill time. The discount applies at the register, not at the prescriber.
4. Confirm the annual cap. Most cards cap savings at around $1,950 to $4,000 per year, after which the discount stops.

Compounded GLP-1: cheaper headlines, narrower legal window

Compounded semaglutide and tirzepatide were the cheapest legal GLP-1s during the 2022 to 2025 shortage. That changed in late 2024 when the FDA declared both shortages resolved and pulled both molecules off the federal shortage list ^[3]. The legal lane for 503A compounding narrowed sharply.

Compounding can still happen, but only under specific conditions: the prescription must be patient-specific, the formulation must be meaningfully different from the commercial product (often a B12 add-on or a non-standard dose), and the pharmacy must be a state-licensed 503A. Large telehealth platforms that previously advertised compounded GLP-1s for $99 a month have either raised prices, restructured offerings around personalized formulations, or exited the category entirely.

What current pricing actually looks like for legitimate 503A compounded GLP-1 in May 2026:

• Compounded semaglutide: $129 to $249 a month from licensed telehealth providers
• Compounded tirzepatide: $179 to $399 a month
• Headline prices under $130 usually require 3 to 12 month prepayment and a starter-dose lock-in

Compounded GLP-1s use the same active molecule as the brand products but are not FDA-approved as a finished injectable. The drug, the diluent, and the vial are all subject to the compounding pharmacy's quality control rather than a manufacturer's NDA. For most adults this is an acceptable tradeoff. For pregnant or nursing patients, people with a personal or family history of medullary thyroid cancer or MEN2, and anyone with a pancreatitis history, it is not.

The compounded route is no longer obviously cheaper than LillyDirect or NovoCare for most people. By the time you add membership fees, lab work, shipping, and the standard dose-tier price jumps at 7.5 mg or higher, a "$99" plan often lands at $200 to $300 a month. LillyDirect Zepbound at $299 is hard to beat once the math is honest.

Insurance copays: the cheap path nobody plans for

If your insurance covers your GLP-1 at a normal Tier 2 or Tier 3 copay, you almost always beat every cash-pay program. The catch is that insurance coverage for GLP-1s splits hard along indication lines.

For type 2 diabetes:

• Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, and Bydureon are covered by the large majority of commercial plans and most Medicaid programs.
• Typical copay tiers run $25 to $75 a month for a 30-day fill.
• Manufacturer savings cards stack on top of insurance and routinely deliver $25 for Mounjaro and Ozempic.

For obesity without diabetes:

• Wegovy and Zepbound are covered by roughly a quarter to a third of commercial plans, with state and employer variation.
• Where covered, copays are usually $50 to $150 a month.
• Medicare Part D does not cover anti-obesity medications under current law ^[4], with a narrow exception under discussion for the proposed mid-2026 Medicare GLP-1 Bridge Program.

If you have insurance and have not actually called the pharmacy benefit line to verify coverage, do that before you order anything cash-pay. The cheapest GLP-1 in your specific situation might be the $35 copay you have not checked.

Medicare, Medicaid, and the public-payer maze

Medicare Part D covers GLP-1 receptor agonists when the indication is type 2 diabetes ^[4]. Ozempic, Mounjaro, Trulicity, Victoza, and Rybelsus are all on most Part D formularies. The patient pays the standard Part D cost-sharing, which under the 2025 Inflation Reduction Act caps total out-of-pocket spending at $2,000 a year across all Part D drugs.

Medicare Part D does not cover GLP-1s when the only indication is obesity or weight management. Wegovy and Zepbound for weight loss are statutorily excluded under the same provision that has kept Medicare out of anti-obesity drugs since 2003. The Wegovy approval for cardiovascular risk reduction in obesity with established heart disease created a narrow Medicare coverage path under that specific indication, but the underlying obesity-only use is still excluded.

Medicaid coverage of GLP-1s varies by state and by indication. As of 2026, most state Medicaid programs cover GLP-1s for type 2 diabetes, and a growing minority cover Wegovy or Saxenda for obesity, often with prior authorization, BMI thresholds, and step therapy requirements. There is no national rule. Check your state's preferred drug list.

The old GLP-1s: cheap by 2020 standards, not anymore

Before semaglutide and tirzepatide, the GLP-1 class meant exenatide (Byetta and Bydureon), liraglutide (Victoza and Saxenda), and dulaglutide (Trulicity). These older drugs are still on the market, still FDA-approved, and in a few cases still cheaper than the newer molecules for cash buyers.

The honest read: for type 2 diabetes, the authorized generic liraglutide (sold for the Victoza indication) and exenatide with a GoodRx coupon can sometimes beat the LillyDirect and NovoCare numbers. For weight loss, the older drugs do not beat tirzepatide and semaglutide on either price or effect. Saxenda is the only liraglutide formulation FDA-approved for obesity and there is no generic for that indication. The molecule is the same as Victoza, but the price reflects the active patent protection on the obesity-indicated product.

Generic GLP-1s: not yet, and not soon

There is no true generic for semaglutide or tirzepatide in the US in 2026. Semaglutide's earliest possible generic entry depends on Novo Nordisk's patent portfolio, with the core composition patents extending into 2031 to 2033. Tirzepatide's patents run later, into the mid-2030s. Compounded versions are not generics; they are individually prepared prescriptions under a different regulatory regime.

Authorized generic liraglutide for the Victoza (type 2 diabetes) indication launched in 2024 and now sells for roughly $400 to $500 a month at most retail pharmacies. That is the only "generic" GLP-1 actually on the US market today, and it does not cover the Saxenda obesity indication.

GoodRx coupons help on the older molecules (exenatide, liraglutide, dulaglutide) and occasionally trim a small percentage off Ozempic or Mounjaro at independent pharmacies ^[5]. They do almost nothing for Wegovy or Zepbound, where manufacturer cash programs already undercut what GoodRx can negotiate.

Decision tree: pick the cheapest GLP-1 for your situation

The right answer depends on a small number of variables. Walk down this tree.

1. Do you have commercial insurance?

• Yes, and your plan covers your GLP-1 for your indication. Use the prescription benefit plus the manufacturer savings card. Target price: $25 to $75 a month. Stop here.
• Yes, but your plan excludes the drug you want. Continue to step 2.
• No (uninsured, Medicare, or Medicaid without GLP-1 coverage). Continue to step 2.

2. Do you want tirzepatide or semaglutide?

• Tirzepatide. Go to LillyDirect Zepbound vials at $299 (2.5 mg), $399 (5 mg), or $449 (7.5 to 15 mg) ^[1]. This is the floor for FDA-approved tirzepatide.
• Semaglutide. Go to NovoCare Wegovy at $199 starter, then $349 ongoing ^[2]. This is the floor for FDA-approved injectable semaglutide. Oral Wegovy tablets at $149 to $199 are a needle-free alternative at a similar price.
• Either is fine, just want the cheapest legal option. LillyDirect Zepbound 2.5 mg at $299 wins by a small margin and tirzepatide produces larger average weight loss in head-to-head trials.

3. Is the manufacturer cash price still too high?

• Check compounded semaglutide ($129 to $249) or compounded tirzepatide ($179 to $399) from a state-licensed 503A telehealth provider that names its pharmacy partner. Accept the FDA-approval tradeoff.
• Check whether your state Medicaid covers GLP-1s for your indication. Coverage has expanded in 2025 to 2026 in many states.
• Check whether you qualify for a manufacturer patient assistance program (the Lilly Cares Foundation and the Novo Nordisk Patient Assistance Program both have income-based free-medication tracks for uninsured patients below specific income thresholds).

4. Do you have type 2 diabetes specifically?

• Older molecules become competitive. Authorized generic liraglutide for Victoza, exenatide with GoodRx, and dulaglutide with the Trulicity savings card all bring the cash price under $500 for some patients. The weight-loss effect is smaller, but for glycemic control they work.

Hidden costs that wreck a "cheap" headline price

The advertised monthly price is rarely the all-in cost. Before you commit, add:

• Membership or platform fees: $20 to $50 a month on many telehealth services.
• Required lab work: $50 to $200 every 3 to 6 months if not bundled.
• Shipping: $15 to $30 per refill on services that do not include it.
• Dose-tier price jumps: most platforms charge 20 to 50 percent more at 7.5 mg or higher, so a "$129 starter" becomes $200+ within three months.
• Multi-month prepay locks: many of the lowest headline prices require 3, 6, or 12 month upfront payment with no refund if you stop.
• Initial consultation: $19 to $129 one-time fee on some platforms.

A flat $299 from LillyDirect with no membership, no platform fee, free shipping, and one transparent dose-tier structure ends up cheaper than a $129 "starter" plan from a telehealth bundle by month two for many patients ^[1].

HSA, FSA, and the effective discount

GLP-1 medications prescribed for a qualifying medical condition (type 2 diabetes, obesity, sleep apnea, established cardiovascular disease) are HSA and FSA eligible. That alone is a 22 to 37 percent effective discount depending on your federal and state marginal tax brackets. A $349 NovoCare Wegovy month costs roughly $220 to $270 out of pocket after the tax shield. Run that math before assuming you cannot afford a brand-name option.

What "cheap" should not mean

Sub-$100 monthly GLP-1 offers in 2026 fall into three buckets. One is legitimate but limited (introductory promotional pricing that resets to $200+ by month two). One is borderline (503A compounded products from pharmacies with weak quality oversight, where the price is real but the medication consistency is not). And one is illegal and unsafe (gray-market "research peptide" vials sold by unlicensed online vendors with no prescription, no Certificate of Analysis, and no patient-specific compounding record).

The third bucket is where actual patient harm happens. The FDA has issued multiple warnings since 2023 about unapproved semaglutide and tirzepatide products sold for human use without a prescription ^[3]. Reports of injection-site infections, dosing errors from inconsistent vial concentrations, and active ingredient that tests as a different molecule entirely have all appeared in adverse event databases. Paying $299 a month to Eli Lilly for a vial that came out of an FDA-inspected facility is a different product than paying $40 a vial to a peptide site that ships from overseas.

Frequently asked questions

What is the absolute cheapest legal GLP-1 in 2026?

For FDA-approved drugs paid in cash, LillyDirect Self Pay Zepbound vials at $299 a month for the 2.5 mg dose are the floor. For semaglutide specifically, NovoCare Wegovy at $199 starter and $349 ongoing is the cheapest brand path.

What is the cheapest GLP-1 without insurance?

LillyDirect Zepbound vials at $299 to $449 a month for FDA-approved tirzepatide, or NovoCare Wegovy at $199 starter and $349 ongoing for FDA-approved semaglutide. Compounded versions can be lower but are not FDA-approved.

Is compounded GLP-1 still the cheapest option in 2026?

Not always. After the FDA declared the semaglutide and tirzepatide shortages resolved, the legal compounding window narrowed and average prices rose. Once membership fees and dose-tier jumps are included, LillyDirect Zepbound at $299 often beats a compounded plan by month two.

Can Medicare Part D cover Zepbound or Wegovy for weight loss?

Not under current law. Medicare Part D covers GLP-1s for type 2 diabetes, not for obesity-only indications. Wegovy gained narrow Medicare coverage for cardiovascular risk reduction in patients with obesity and established heart disease.

Does GoodRx work on Ozempic or Mounjaro?

GoodRx coupons exist for both drugs but the discount is usually small because the manufacturer savings cards already undercut what GoodRx negotiates. GoodRx is more useful on older GLP-1s like exenatide, liraglutide, and dulaglutide.

Is there a generic for Ozempic or Mounjaro?

No. Semaglutide patents run into the early 2030s; tirzepatide patents run into the mid-2030s. The only authorized generic in the GLP-1 class is liraglutide for the Victoza (type 2 diabetes) indication.

What does Byetta or exenatide cost in 2026?

Exenatide BID (Byetta) runs roughly $400 to $600 a month with a GoodRx coupon at most US pharmacies. Exenatide ER (Bydureon BCise) runs $700 to $900. Both are FDA-approved and older than semaglutide and tirzepatide, with weaker weight-loss effects.

Can I get GLP-1 for $25 a month?

Only if you have commercial insurance with GLP-1 coverage for your indication and you apply the manufacturer savings card on top. Without insurance, $25 is not achievable for any FDA-approved GLP-1 in 2026.

How does TrumpRx fit into cheap GLP-1 access?

TrumpRx.gov was announced as a federal portal to consolidate manufacturer cash-pay programs. Initial Zepbound and Wegovy pricing through the portal is expected to land near $350 a month, similar to LillyDirect and NovoCare. The portal does not produce a new low price; it routes to existing manufacturer programs.

Are oral GLP-1 pills cheaper than the injections?

Oral Wegovy tablets sit at $149 to $199 a month on the self-pay starter doses, which is cheaper than the cheapest brand injection. Rybelsus (older oral semaglutide) is more expensive at retail but drops to $25 with a savings card for type 2 diabetes.

Can I use an HSA or FSA for a GLP-1?

Yes, for a qualifying medical indication like type 2 diabetes or obesity (BMI 30+ or 27+ with a comorbidity). The tax shield is an effective 22 to 37 percent discount depending on your bracket, so a $349 cash price often nets to $220 to $270 out of pocket.

Is the cheapest GLP-1 also the most effective?

Same molecule, same dose, same effect. LillyDirect Zepbound vials are the same tirzepatide as Zepbound pens. NovoCare Wegovy pens are the same semaglutide as a $1,300 retail Wegovy pen. The price difference is supply chain and device cost, not pharmacology.

The bottom line

The cheapest GLP-1 question in 2026 has two real answers and a lot of noise. If you have commercial insurance and a covered indication, the manufacturer savings card route to $25 a month is unbeatable. If you do not, LillyDirect Self Pay Zepbound at $299 to $449 a month and NovoCare Self Pay Wegovy at $199 starter and $349 ongoing are the floor for FDA-approved GLP-1 in the US. Everything else (compounded, off-shore peptide, GoodRx on retail pens, older molecules) is either narrower in availability, riskier in regulation, or only marginally cheaper once the full price is honest.